http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2011223655-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_299e61160b333bde03bc2fd31dcf5752 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2011-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d19396b92a9fc12277d47c41c3edf58c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67aec7577dc7a8f12aa39f167e776c42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aae9a943c38996e2435e903e1fcd3b55 |
| publicationDate | 2012-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2011223655-A1 |
| titleOfInvention | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| abstract | The present invention provides diagnostic methods for predicting the effectiveness of treatment of an ovarian cancer patient with an IGF- IR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-IR kinase inhibitor, comprising assessing whether the tumor cells possess mutant K-RAS. The present invention thus provides a method of identifying patients with ovarian cancer who are most likely to benefit from treatment with an IGF- IR kinase inhibitor. Improved methods for treating cancer patients with IGF-IR kinase inhibitors that incorporate this methodology are also provided. The present invention also provides diagnostic methods for predicting the effectiveness of treatment of cancer patients with IGF-IR kinase inhibitors, based on a determination of the mutation status of the genes K-RAS, B-RAF, PTEN and PIK3CA, which can be used to identify tumor cell types that will be sensitive to IGF-IR kinase inhibitors, and also those that will be insensitive. |
| priorityDate | 2010-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1190.